The authors confirmed the PI3K/mTOR signaling pathway as a therapeutic vulnerability in various DIPG-derived models by performing CRISPR-Cas9 screens and high-throughput drug screens and pinpointed paxalisib as a potential drug for DIPG irrespective of PI3K mutational status. The gene discussed is MTOR; the disease is diffuse intrinsic pontine glioma.